Ron Bentsur Nuvectis Pharma, Inc. (NVCT) insider trading activity

Ron Bentsur is Chairman & CEO of Nuvectis Pharma, Inc.. Currently has a direct ownership of 3.25 Million shares of NVCT, which is worth approximately $19.8 Million. The most recent transaction as insider was on Mar 23, 2023, when has been sold 230 shares (Common Stock) at a price of $12.13 per share, resulting in proceeds of $2,789. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 3.25M

0% 3M change

0.32% 12M change

Total Value Held $19.8 Million

RON BENTSUR Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 23 2023	BUY Open market or private purchase	$2,789 $12.13 p/Share	230 Added 0.01%	3,228,329 Common Stock
Mar 21 2023	BUY Open market or private purchase	$5,798 $12.08 p/Share	480 Added 0.01%	3,228,099 Common Stock
Mar 15 2023	BUY Open market or private purchase	$5,236 $10.91 p/Share	480 Added 0.01%	3,227,619 Common Stock
Mar 14 2023	BUY Open market or private purchase	$18,228 $10.85 p/Share	1,680 Added 0.05%	3,227,139 Common Stock
Jan 12 2023	BUY Grant, award, or other acquisition	-	210,000 Added 6.11%	3,225,459 Common Stock
Nov 30 2022	BUY Open market or private purchase	$1,117 $7.45 p/Share	150 Added 0.0%	3,015,459 Common Stock
Nov 29 2022	BUY Open market or private purchase	$1,117 $7.45 p/Share	150 Added 0.0%	3,015,309 Common Stock
Nov 28 2022	BUY Open market or private purchase	$1,110 $7.4 p/Share	150 Added 0.0%	3,015,159 Common Stock
Nov 25 2022	BUY Open market or private purchase	$1,107 $7.38 p/Share	150 Added 0.0%	3,015,009 Common Stock
Nov 18 2022	BUY Open market or private purchase	$3,615 $7.23 p/Share	500 Added 0.02%	3,014,859 Common Stock
Nov 17 2022	BUY Open market or private purchase	$1,810 $7.24 p/Share	250 Added 0.01%	3,014,359 Common Stock
Nov 10 2022	BUY Open market or private purchase	$7,070 $7.07 p/Share	1,000 Added 0.03%	3,014,109 Common Stock
Sep 30 2022	BUY Open market or private purchase	$3,730 $7.46 p/Share	500 Added 0.02%	3,013,109 Common Stock
Sep 28 2022	BUY Open market or private purchase	$3,615 $7.23 p/Share	500 Added 0.02%	3,012,609 Common Stock
Sep 26 2022	BUY Open market or private purchase	$3,845 $7.69 p/Share	500 Added 0.02%	3,012,109 Common Stock
Sep 23 2022	BUY Open market or private purchase	$7,930 $7.93 p/Share	1,000 Added 0.03%	3,011,609 Common Stock
Sep 02 2022	BUY Open market or private purchase	$10,044 $8.37 p/Share	1,200 Added 0.04%	3,010,609 Common Stock
Sep 01 2022	BUY Open market or private purchase	$4,055 $8.11 p/Share	500 Added 0.02%	3,009,409 Common Stock
Aug 29 2022	BUY Open market or private purchase	$9,070 $9.07 p/Share	1,000 Added 0.03%	3,008,909 Common Stock
Aug 23 2022	BUY Open market or private purchase	$4,500 $9.0 p/Share	500 Added 0.02%	3,007,909 Common Stock
Aug 19 2022	BUY Open market or private purchase	$44,950 $8.99 p/Share	5,000 Added 0.17%	3,007,409 Common Stock
Aug 18 2022	BUY Open market or private purchase	$123,775 $8.58 p/Share	14,426 Added 0.48%	3,002,409 Common Stock
Aug 11 2022	BUY Open market or private purchase	$165,220 $8.4 p/Share	19,669 Added 0.65%	2,987,983 Common Stock
Jun 29 2022	BUY Open market or private purchase	$42,994 $11.62 p/Share	3,700 Added 0.12%	2,968,314 Common Stock
Jun 28 2022	BUY Open market or private purchase	$3,546 $11.82 p/Share	300 Added 0.01%	2,964,614 Common Stock

Also insider at

XAIR

Beyond Air, Inc. Healthcare

Director

Ron Bentsur

Chairman & CEO

Garden City, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NVCT shares.

Notify only if

Value

Insider Trading

Get notified when an Nuvectis Pharma, Inc. insider buys or sells NVCT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Nuvectis Pharma, Inc.

Track Activities on NVCT

Account